Claims for Patent: 6,403,649

Summary for Patent: 6,403,649

Title:	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
Abstract:	The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
Inventor(s):	Woodward; David F. (El Toro, CA), Andrews; Steven W. (Rancho Santa Marguerita, CA), Burk; Robert M. (Irvine, CA), Garst; Michael E. (Newport Beach, CA)
Assignee:	Allergan Sales, Inc. (Irvine, CA)
Application Number:	09/519,834
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,403,649
Patent Claims:	1. A compound, that is cyclopentane N-ethyl heptenamide-5-cis-2-(3.alpha.-hydroxy-5-phenyl-1-trans-pentenyl)-3,5-dihyd roxy, [1.sub..alpha., 2.sub..beta., 3.sub..alpha., 5.sub..alpha. ]). 2. A method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of the compound of claim 1. 3. A method of treating glaucoma which comprises applying to the eye an amount sufficient to treat glaucoma of the compound of claim 1.